https://www.selleckchem.com/pr....oducts/pyridostatin-
Background Although increased early detection, diagnosis and treatment have improved the outcome of breast cancer patients, prognosis estimation still poses challenges due to the disease heterogeneity. Accumulating data indicated an evident correlation between tumor immune microenvironment and clinical outcomes. Objective To construct an immune-related signature that can estimate disease prognosis and patient survival in breast cancer. Methods Gene expression profiles and clinical data of breast cancer patient